Header Logo

Connection

Clare Cutland to Double-Blind Method

This is a "connection" page, showing publications Clare Cutland has written about Double-Blind Method.
Connection Strength

0,486
  1. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
    View in: PubMed
    Score: 0,045
  2. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
    View in: PubMed
    Score: 0,044
  3. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
    View in: PubMed
    Score: 0,043
  4. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV. 2020 02; 7(2):e91-e103.
    View in: PubMed
    Score: 0,040
  5. Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes. Vaccine. 2019 08 23; 37(36):5397-5403.
    View in: PubMed
    Score: 0,039
  6. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres. Vaccine. 2019 03 22; 37(13):1876-1884.
    View in: PubMed
    Score: 0,037
  7. Influenza Vaccination during Pregnancy and Protection against Pertussis. N Engl J Med. 2018 03 29; 378(13):1257-1258.
    View in: PubMed
    Score: 0,036
  8. Efficacy of Maternal Influenza Vaccination Against All-Cause Lower Respiratory Tract Infection Hospitalizations in Young Infants: Results From a Randomized Controlled Trial. Clin Infect Dis. 2017 10 01; 65(7):1066-1071.
    View in: PubMed
    Score: 0,034
  9. Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization: Secondary Analysis of a Randomized Clinical Trial. JAMA Pediatr. 2016 09 01; 170(9):840-7.
    View in: PubMed
    Score: 0,032
  10. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014 Sep 04; 371(10):918-31.
    View in: PubMed
    Score: 0,028
  11. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS. 2013 Jan 28; 27(3):369-79.
    View in: PubMed
    Score: 0,025
  12. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
    View in: PubMed
    Score: 0,022
  13. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007 Mar 22; 25(13):2451-7.
    View in: PubMed
    Score: 0,016
  14. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. J Clin Virol. 2006 Jul; 36(3):215-21.
    View in: PubMed
    Score: 0,016
  15. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine. 2006 Mar 20; 24(13):2432-9.
    View in: PubMed
    Score: 0,015
  16. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis. 2005 May 15; 40(10):1511-8.
    View in: PubMed
    Score: 0,014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.